《大行報告》花旗:新奧(02688.HK)斥不逾1億美元購股作獎勵計劃 積極重拾投資者信心
花旗發表報告指,新奧(02688.HK)公布將會斥資不多於1億美元等值港元購買普通股份作獎勵計劃,該行視此舉動為公司積極重拾投資者信心的催化劑。該行指,自8月份公布中期業績後,其股價大跌,可能是因為公司就業績表現的解釋不尋常。據該行了解,該公司董事局成員本周將在香港和新加坡與投資者會面,相信將透過提高這些問題的透明度來解決投資者的擔憂。
該行表示,新奧今月股價跌至自2017年低位,並自2021年8月高位跌約65%,現時估值便宜,相當於2023年市盈率預測8.4倍,股息率為4.2%,該行認為是買入時機,給予其目標價為83元,評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.